USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity

Robyn Laura Kosinsky, Maria Zerche, Dominik Saul, Xin Wang, Luisa Wohn, Florian Wegwitz, Yvonne Begus-Nahrmann, Steven A. Johnsen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

USP22, the deubiquitinating subunit of the SAGA transcriptional cofactor complex, is a member of an 11-gene “death-from-cancer” signature. USP22 has been considered an attractive therapeutic target since high levels of its expression were associated with distant metastasis, poor survival, and high recurrence rates in a wide variety of solid tumors, including colorectal cancer (CRC). We sought to investigate the role of Usp22 during tumorigenesis in vivo using a mouse model for intestinal carcinogenesis with a tissue-specific Usp22 ablation. In addition, we assessed the effects of USP22 depletion in human CRC cells on tumorigenic potential and identified underlying molecular mechanisms. For the first time, we report that USP22 has an unexpected tumor-suppressive function in vivo. Intriguingly, intestine-specific Usp22 deletion exacerbated the tumor phenotype caused by Apc mutation, resulting in significantly decreased survival and higher intestinal tumor incidence. Accordingly, human CRC cells showed increased tumorigenic properties upon USP22 reduction in vitro and in vivo and induced gene expression signatures associated with an unfavorable outcome in CRC patients. Notably, USP22 loss resulted in increased mTOR activity with the tumorigenic properties elicited by the loss of USP22 being reversible by mTOR inhibitor treatment in vitro and in vivo. Here, we demonstrate that USP22 can exert tumor-suppressive functions in CRC where its loss increases CRC burden by modulating mTOR activity. Importantly, our data uncover a tumor- and context-specific role of USP22, suggesting that USP22 expression could serve as a marker for therapeutic stratification of cancer patients.

Original languageEnglish (US)
JournalCell Death and Differentiation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Colorectal Neoplasms
Neoplasms
Carcinogenesis
Survival
Neoplasm Genes
Transcriptome
Intestines
Therapeutics
Neoplasm Metastasis
Phenotype
Recurrence
Mutation
Incidence

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity. / Kosinsky, Robyn Laura; Zerche, Maria; Saul, Dominik; Wang, Xin; Wohn, Luisa; Wegwitz, Florian; Begus-Nahrmann, Yvonne; Johnsen, Steven A.

In: Cell Death and Differentiation, 01.01.2019.

Research output: Contribution to journalArticle

Kosinsky, Robyn Laura ; Zerche, Maria ; Saul, Dominik ; Wang, Xin ; Wohn, Luisa ; Wegwitz, Florian ; Begus-Nahrmann, Yvonne ; Johnsen, Steven A. / USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity. In: Cell Death and Differentiation. 2019.
@article{c3ba476a219b4a48bf5a4d294226b741,
title = "USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity",
abstract = "USP22, the deubiquitinating subunit of the SAGA transcriptional cofactor complex, is a member of an 11-gene “death-from-cancer” signature. USP22 has been considered an attractive therapeutic target since high levels of its expression were associated with distant metastasis, poor survival, and high recurrence rates in a wide variety of solid tumors, including colorectal cancer (CRC). We sought to investigate the role of Usp22 during tumorigenesis in vivo using a mouse model for intestinal carcinogenesis with a tissue-specific Usp22 ablation. In addition, we assessed the effects of USP22 depletion in human CRC cells on tumorigenic potential and identified underlying molecular mechanisms. For the first time, we report that USP22 has an unexpected tumor-suppressive function in vivo. Intriguingly, intestine-specific Usp22 deletion exacerbated the tumor phenotype caused by Apc mutation, resulting in significantly decreased survival and higher intestinal tumor incidence. Accordingly, human CRC cells showed increased tumorigenic properties upon USP22 reduction in vitro and in vivo and induced gene expression signatures associated with an unfavorable outcome in CRC patients. Notably, USP22 loss resulted in increased mTOR activity with the tumorigenic properties elicited by the loss of USP22 being reversible by mTOR inhibitor treatment in vitro and in vivo. Here, we demonstrate that USP22 can exert tumor-suppressive functions in CRC where its loss increases CRC burden by modulating mTOR activity. Importantly, our data uncover a tumor- and context-specific role of USP22, suggesting that USP22 expression could serve as a marker for therapeutic stratification of cancer patients.",
author = "Kosinsky, {Robyn Laura} and Maria Zerche and Dominik Saul and Xin Wang and Luisa Wohn and Florian Wegwitz and Yvonne Begus-Nahrmann and Johnsen, {Steven A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41418-019-0420-8",
language = "English (US)",
journal = "Cell Death and Differentiation",
issn = "1350-9047",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity

AU - Kosinsky, Robyn Laura

AU - Zerche, Maria

AU - Saul, Dominik

AU - Wang, Xin

AU - Wohn, Luisa

AU - Wegwitz, Florian

AU - Begus-Nahrmann, Yvonne

AU - Johnsen, Steven A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - USP22, the deubiquitinating subunit of the SAGA transcriptional cofactor complex, is a member of an 11-gene “death-from-cancer” signature. USP22 has been considered an attractive therapeutic target since high levels of its expression were associated with distant metastasis, poor survival, and high recurrence rates in a wide variety of solid tumors, including colorectal cancer (CRC). We sought to investigate the role of Usp22 during tumorigenesis in vivo using a mouse model for intestinal carcinogenesis with a tissue-specific Usp22 ablation. In addition, we assessed the effects of USP22 depletion in human CRC cells on tumorigenic potential and identified underlying molecular mechanisms. For the first time, we report that USP22 has an unexpected tumor-suppressive function in vivo. Intriguingly, intestine-specific Usp22 deletion exacerbated the tumor phenotype caused by Apc mutation, resulting in significantly decreased survival and higher intestinal tumor incidence. Accordingly, human CRC cells showed increased tumorigenic properties upon USP22 reduction in vitro and in vivo and induced gene expression signatures associated with an unfavorable outcome in CRC patients. Notably, USP22 loss resulted in increased mTOR activity with the tumorigenic properties elicited by the loss of USP22 being reversible by mTOR inhibitor treatment in vitro and in vivo. Here, we demonstrate that USP22 can exert tumor-suppressive functions in CRC where its loss increases CRC burden by modulating mTOR activity. Importantly, our data uncover a tumor- and context-specific role of USP22, suggesting that USP22 expression could serve as a marker for therapeutic stratification of cancer patients.

AB - USP22, the deubiquitinating subunit of the SAGA transcriptional cofactor complex, is a member of an 11-gene “death-from-cancer” signature. USP22 has been considered an attractive therapeutic target since high levels of its expression were associated with distant metastasis, poor survival, and high recurrence rates in a wide variety of solid tumors, including colorectal cancer (CRC). We sought to investigate the role of Usp22 during tumorigenesis in vivo using a mouse model for intestinal carcinogenesis with a tissue-specific Usp22 ablation. In addition, we assessed the effects of USP22 depletion in human CRC cells on tumorigenic potential and identified underlying molecular mechanisms. For the first time, we report that USP22 has an unexpected tumor-suppressive function in vivo. Intriguingly, intestine-specific Usp22 deletion exacerbated the tumor phenotype caused by Apc mutation, resulting in significantly decreased survival and higher intestinal tumor incidence. Accordingly, human CRC cells showed increased tumorigenic properties upon USP22 reduction in vitro and in vivo and induced gene expression signatures associated with an unfavorable outcome in CRC patients. Notably, USP22 loss resulted in increased mTOR activity with the tumorigenic properties elicited by the loss of USP22 being reversible by mTOR inhibitor treatment in vitro and in vivo. Here, we demonstrate that USP22 can exert tumor-suppressive functions in CRC where its loss increases CRC burden by modulating mTOR activity. Importantly, our data uncover a tumor- and context-specific role of USP22, suggesting that USP22 expression could serve as a marker for therapeutic stratification of cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85073814919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073814919&partnerID=8YFLogxK

U2 - 10.1038/s41418-019-0420-8

DO - 10.1038/s41418-019-0420-8

M3 - Article

C2 - 31527800

AN - SCOPUS:85073814919

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

SN - 1350-9047

ER -